Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
Filgotinib
Lakefront Biotherapeutics NV
Ulcerative Colitis
2 trials -
Filgotinib
Lakefront Biotherapeutics NV
Ankylosing Spondylitis
3 trials -
Filgotinib
Lakefront Biotherapeutics NV
Psoriatic Arthritis
4 trials -
Filgotinib
Lakefront Biotherapeutics NV
Crohn's Disease
2 trials -
GLPG CAR T-cell therapy
Lakefront Biotherapeutics NV
Hematological Malignancies
1 trial -
GLPG1690
Lakefront Biotherapeutics NV
Idiopathic Pulmonary Fibrosis
2 trials -
Filgotinib
Lakefront Biotherapeutics NV
Inflammatory Bowel Disease
1 trial -
Filgotinib
Lakefront Biotherapeutics NV
Fistulizing Crohn's Disease
1 trial -
Filgotinib
Lakefront Biotherapeutics NV
Noninfectious Uveitis
1 trial -
Filgotinib
Lakefront Biotherapeutics NV
Small Bowel Crohn's Disease
1 trial -
GLPG0259 oral capsule
Lakefront Biotherapeutics NV
Rheumatoid Arthritis
1 trial -
GLPG0634
Lakefront Biotherapeutics NV
Rheumatoid Arthritis
4 trials -
GLPG0634
Lakefront Biotherapeutics NV
Crohn's Disease
1 trial -
GLPG0974
Lakefront Biotherapeutics NV
Ulcerative Colitis
1 trial -
GLPG1205
Lakefront Biotherapeutics NV
Ulcerative Colitis
1 trial -
GLPG1205
Lakefront Biotherapeutics NV
Idiopathic Pulmonary Fibrosis
1 trial -
GLPG1690
Lakefront Biotherapeutics NV
Systemic Sclerosis
2 trials -
GLPG1690 600 mg QD
Lakefront Biotherapeutics NV
Idiopathic Pulmonary Fibrosis
1 trial -
GLPG1837 dose 1
Lakefront Biotherapeutics NV
Cystic Fibrosis
2 trials -
GLPG1972
Lakefront Biotherapeutics NV
Osteoarthritis
1 trial -
GLPG2222 150 mg q.d.
Lakefront Biotherapeutics NV
Cystic Fibrosis
1 trial -
GLPG2222 50 mg
Lakefront Biotherapeutics NV
Cystic Fibrosis
1 trial -
GLPG2737
Lakefront Biotherapeutics NV
Autosomal Dominant Polycystic Kidney Disease
1 trial -
GLPG2737
Lakefront Biotherapeutics NV
Cystic Fibrosis
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources